why choose us

First received: August 31, 2022

Clinical Trial: Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Head and Neck Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase I Trial of Re-Irradiation With Concurrent Chemotherapy in Combination With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Squamous Cell Carcinoma

Brief Summary: The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after treatment.Participation in the study should last for about 15 months while participants receive tislelizumab and chemoradiotherapy with pamiparib.Afterwards, they will return to the clinic for follow up every 4…

Read more